Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)

Creative Commons License

Kalra S., Atkin S., Cervera A., Das A. K., DEMİR Ö., DEMİR T., ...More

ADVANCES IN THERAPY, vol.35, no.7, pp.928-936, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 35 Issue: 7
  • Publication Date: 2018
  • Doi Number: 10.1007/s12325-018-0712-2
  • Journal Name: ADVANCES IN THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.928-936
  • Keywords: Co-formulation, Consensus, Hypoglycemia, IDegAsp, DEGLUDEC/INSULIN ASPART, BASAL, ADULTS
  • Dokuz Eylül University Affiliated: Yes

Abstract

Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4-5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.